Avacta Group (AVCT) AGM 2025 summary

Opening remarks and agenda

• CEO welcomed shareholders and provided an overview of the meeting, highlighting forward-looking statements and recent achievements.

Financial performance review

• $25.5 million remains outstanding on the Heights Convertible Bond, with funds expected to last two and a half years.

• Cash realized from the sale of Launch Diagnostics, with Coris divestment ongoing and near completion.

• Cash management is focused on supporting the R&D pipeline and building IP value.

Board and executive committee updates

• Appointment of a new Chief Medical Officer and a Business Development Advisor, both based in the U.S., to strengthen the management team.